{"schema_version":"secwatch.filing_event.v1","accession":"0001156039-23-000106","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.348535+00:00","generated_at":"2026-06-10T03:47:13.453727+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Elevance Health amends bylaws to align with SEC universal proxy rules","bullets":["Shareholders must provide detailed Schedule 13D-type disclosures on plans, agreements with respect to company securities.","Nominating shareholder must certify compliance with Exchange Act Rule 14a-19 at least 10 days before meeting.","Shareholders soliciting proxies must use a proxy card color other than white (reserved for Board).","Number of nominees a shareholder may propose is capped at number of directors to be elected.","Votes for any nominee not complying with bylaws or Rule 14a-19 may be disregarded."],"urls":{"canonical":"https://secwatch.observer/filing/0001156039-23-000106","json":"https://secwatch.observer/filing/0001156039-23-000106.json","markdown":"https://secwatch.observer/filing/0001156039-23-000106.md","text":"https://secwatch.observer/filing/0001156039-23-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000115603923000106/0001156039-23-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000115603923000106/elv-20231004.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:47:13.453727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09f2f80b00d3482067868798a8943584d9394030","claim":"Elevance Health, Inc.: Amended bylaws to update procedural and informational requirements for director nominations in response to SEC universal proxy rules (effective 2023-10-04).","evidence_excerpt":"On October 4, 2023, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) approved the amendment of the Company’s Bylaws (as so amended, the “Bylaws”) to, among other things, update procedural and informational requirements applicable to director nominations submitted by shareholders in light of the Securities and Exchange Commission’s adoption of “universal proxy” rules as set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000115603923000106/0001156039-23-000106-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-10-04"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}